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Abstract  41 
Context: adrenocortical adenomas (ACAs) are among the most frequent human neoplasias. Genetic 42 
alterations affecting the cAMP/PKA signaling pathway are common in cortisol-producing ACAs, 43 
while activating mutations in the gene encoding β-catenin (CTNNB1) have been reported in a subset 44 
of both benign and malignant adrenocortical tumors. However, the molecular pathogenesis of most 45 
ACAs is still largely unclear. 46 
Objective: aim of the study was to define the genetic landscape of sporadic unilateral ACAs.  47 
Design and setting: next-generation whole-exome sequencing was performed on fresh-frozen tumor 48 
samples and corresponding normal tissue samples.   49 
Patients: 99 patients with ACAs (74 cortisol-producing and 25 endocrine inactive) negative for 50 
p.Leu206Arg PRKACA mutation.  51 
Main outcome measures: identification of known and/or new genetic alterations potentially involved 52 
in adrenocortical tumorigenesis and autonomous hormone secretion, genotype-phenotype correlation.  53 
Results: 706 somatic protein-altering mutations were detected in 88/99 tumors (median: 6 per tumor). 54 
We identified several mutations in genes of the cAMP/PKA pathway, including three novel mutations 55 
in PRKACA, associated with female sex and Cushing’s syndrome. We also found genetic alterations 56 
in different genes involved in the Wnt/β-catenin pathway, associated with larger tumors and endocrine 57 
inactivity, and, notably, in many genes of the Ca2+-signaling pathway. Finally, by comparison of our 58 
genetic data with those available in the literature, we describe a comprehensive genetic landscape of 59 
unilateral ACAs.  60 
Conclusions: This study provides the largest sequencing effort on ACAs up to now. We thereby 61 
identified somatic alterations affecting known and novel pathways potentially involved in adrenal 62 
tumorigenesis. 63 
 64 
 65 
 66 
 67 
 68 
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Introduction 69 
Adrenocortical adenomas (ACAs) are among the most frequent human neoplasias with a prevalence of 70 
2-3% in the general population. They are endocrine inactive in 70% of cases, mostly incidentally-71 
discovered, or associated with autonomous cortisol or aldosterone secretion. The genetic basis of 72 
several adrenal disorders has been elucidated over the last years following classical genetic approaches 73 
and utilizing next-generation sequencing techniques. In particular, the cAMP/protein kinase A (PKA) 74 
pathway plays a central role in adrenocortical growth and steroidogenesis. Specifically, genetic 75 
alterations affecting the cAMP/PKA pathway, such as germline or somatic mutations in genes 76 
encoding the regulatory subunit 1 α of PKA (PRKAR1A), the protein Gsα (GNAS), and the 77 
phosphodiesterases 11A and 8B (PDE11A and PDE8B) have been reported in cortisol-producing 78 
ACAs (CPA) and bilateral micronodular adrenal hyperplasias (1-5).  79 
Recently, we and others have found somatic mutations in the gene encoding the catalytic 80 
subunit α of PKA (PRKACA) in 35-70% of unilateral ACAs associated with Cushing’s syndrome (6-81 
10). These mutations translate into a constitutive activation of PKA by interfering with binding 82 
between its regulatory and catalytic subunits (11). Activating mutations in the gene encoding β-catenin 83 
(CTNNB1) represent another important contributor of adrenocortical growth. At variance with 84 
mutations in PRKACA, CTNNB1 mutations had been reported in both adrenocortical adenomas and 85 
carcinomas with similar prevalence (10-30%) (12-14), and had been most frequently observed in non-86 
cortisol-secreting tumors (15). Moreover, by using SNP array profiling, we have identified the 87 
presence of several recurrent copy number alterations (CNA) in specific chromosomal regions that 88 
may also play a role in the pathogenesis of these tumors (16-17).  89 
Despite these recent advances, the pathogenesis of a large proportion of ACAs has remained 90 
elusive. In particular, despite representing the most frequent subtype, endocrine inactive adenomas are 91 
the least thoroughly investigated, due to their infrequent surgical treatment and thus 92 
underrepresentation in tissue based studies. Therefore, the aim of the current study was to define the 93 
genetic landscape of sporadic unilateral ACAs by next-generation whole-exome sequencing (WES). In 94 
particular, we intended to clarify the molecular mechanisms involved in adrenocortical tumor 95 
development and provide genotype-phenotype correlation studies.  96 
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Methods 97 
Tissue samples, patients, and clinical annotations 98 
Fresh-frozen ACA tissues (n=99) and corresponding blood or normal adrenal tissues were included 99 
from 11 centers belonging to the European Network for the Study of Adrenocortical Tumors (ENSAT, 100 
www.ensat.org). Only histologically confirmed unilateral ACAs were included (18). We selected 101 
endocrine inactive ACAs (EIA) and CPA without known p.Leu206Arg PRKACA mutation (6-10). A 102 
subgroup of patients (n=42) had been included in an earlier report (8). All patients provided written 103 
informed consent and the study was approved by the ethics committee of each participating institution.  104 
Clinical and hormonal data were collected through the ENSAT registry 105 
(https://registry.ensat.org/). Overt Cushing’s syndrome (CS) and subclinical CS (SCS) were diagnosed 106 
according to current guidelines (19) and defined as previously reported (6). The final series consisted 107 
of 74 CPA (39 CS and 35 SCS) and 25 EIA (Table 1).  108 
A comparative analysis was performed with data available from previous WES studies on 109 
CPAs (n=79) (6, 7, 12, 13) and ACC (n=176) (12, 20), and from “The Cancer Genome Atlas” project 110 
(21, https://tcga.data.nci.nih.gov/tcga/tcgaCancerDetails.jsp). 111 
 112 
WES and data analysis 113 
DNA was extracted from fresh-frozen tissues and checked for signs of degradation as previously 114 
described (6). Exomes were enriched in solution and indexed with the SureSelect XT Human All Exon 115 
(50Mb kit, version 5, Agilent Technologies, Santa Clara, CA, USA) for library preparation. 116 
Sequencing was performed as paired-end reads of 100 bp on HiSeq2500 systems (Illumina, San 117 
Diego, CA, USA). Pools of 12 indexed libraries were sequenced on four lanes to an average depth of 118 
coverage between 82x and 170x. Image analysis and base calling were performed with Real-Time 119 
Analysis software (Illumina). Reads were aligned against the human assembly hg19 (GRCh37) using 120 
the Burrows-Wheeler Aligner tool (BWA, v 0.7.5a). Moreover, we performed single-nucleotide 121 
variant and small insertion and deletion (indel) calling specifically for the regions targeted by the 122 
exome enrichment kit, using SAMtools (v 0.1.19). Subsequently the variants were filtered using the 123 
SAMtools varFilter script using default parameters, with the exception of the maximum read depth 124 
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parameter, which we set to 9999. Variant detection was done as described earlier (6). In brief, to 125 
reduce false positives we filtered out variants that were already present in our in-house database 126 
(currently 8,000 exomes) or had variant quality less than 40. Raw read data of the remaining variants 127 
are then manually investigated using the Integrative Genomics Viewer (IGV). The frequency of each 128 
mutated allele was then evaluated in large population genomics projects, such as the EXAC (Broad) 129 
and the “1000 Genomes AF (allele frequency)” data set (Supplementary Table 1). 130 
The Gene Set Enrichment Analysis software (MSigDB database v5.0) (22) was used to 131 
identify enriched gene ontology (GO) terms in ranked lists of genes and to perform gene family and 132 
pathway analysis (1330 gene sets), including the KEGG (Kyoto Encyclopedia of Genes and Genomes) 133 
and the REACTOME pathway (v55) databases.  134 
 135 
In silico analysis 136 
Somatic variants were evaluated by both Polymorphism Phenotyping v2 algorithm tool (PolyPhen-2) 137 
(http://genetics.bwh.harvard.edu/pph2) (23) and SIFT (Sorting Tolerant From Intolerant) algorithm 138 
(http://sift.jcvi.org/index.html) (24) to predict the possible impact of an amino acid substitution on the 139 
structure and function of a human protein. The variants were classified as possibly pathogenic according to 140 
the given thresholds (Supplementary Table 1).  Most interesting recurrent genetic alterations were 141 
evaluated by in silico analysis to predict whether the variants may be damaging. Structural images 142 
were prepared with PyMOL software (www.pymol.org). The 3D structures of the mammalian PKA 143 
holoenzyme containing catalytic subunit α and regulatory subunit 2 β (PRKACA-PRKAR2B), the 144 
stimulatory G-protein α subunit (GNAS, isophorm 15), and the ryanodine receptor RYR1 were 145 
acquired from Protein Data Bank (http://www.rcsb.org/pdb/, entries 3TNP, 1AZS, and 4UWA, 146 
respectively). Aminoacid changes induced by mutations were identified and displayed using the 147 
Chimera v1.10 Software. 148 
 149 
Copy number alterations 150 
We compared the results of WES in the present study with previously published CNA data by SNP 151 
array profiling (17) available in 14/99 patients.  152 
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Transcriptome analysis  153 
Transcriptome analysis was performed by Affymetrix HGU133Plus2, as previously described (25), on 154 
an independent cohort of 41 ACAs, including 11 EIAs and 30 CPAs (20 CS and 10 SCS). Targeted 155 
next-generation sequencing (AmpliSeq design, IonTorrent sequencing) for CTNNB1 (Ser45 hotspot, 156 
exons 7 and 8), PRKACA (L206 hotspot), GNAS (R201 hotspot), PRKACB and PRKAR1A was 157 
performed on 37/41 ACAs. Reads were aligned using the human genome assembly hg19 (GRCh37) 158 
and variant calling was performed using Torrent Suite Software (v. 4.2.1). Variants were annotated by 159 
ANNOVAR package (March, 22nd 2015 release). Variants were visually validated by IGV. Mutations 160 
were validated by Sanger sequencing. The mutation status for CTNNB1 was not available for one 161 
ACA, whereas the one for PRKAR1A and PRKACB was not available in four ACAs. 162 
Transcriptome data were analyzed in R (https://cran.r-project.org/). Unsupervised hierarchical 163 
clustering was performed using hclust based on the top 1000 variable transcripts. Differential gene 164 
expression was generated with Limma (Linear Models for Microarray Data (26)) R package, using 165 
Benjamini-Hochberg correction to adjust p-values. An extensive list of calcium-signaling related 166 
genes was provided by the KEGG “Calcium Signaling Pathway” gene list. Enrichment in these 167 
calcium genes was sought among the differentially expressed genes, using the Fisher exact test. 168 
 169 
Statistical analysis 170 
Unsupervised complete linkage clustering was performed on the rows and columns using the 171 
Hamming distance as a similarity metric, to investigate interdependency among genetic alterations. 172 
The Fisher’s exact or Chi-square tests, and Mann-Whitney U test were used to investigate dichotomic 173 
and continuous variables, where appropriate. Kruskal-Wallis test, followed by Bonferroni post-hoc 174 
test, was performed for comparison among groups for non-normally distributed variables. Data are 175 
shown as median and ranges, if not otherwise specified. Statistical analyses were made using 176 
GraphPad Prism (version 5.0, La Jolla, CA, USA) and SPSS Software (version 21, SPSS Inc., 177 
Chicago, IL, USA). P values <0.05 were considered as statistically significant.  178 
 179 
 180 
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Results 181 
Overview of genetic findings 182 
Clinical and hormonal characteristics together with the genetic data of patients are provided in Table 183 
1. We identified 706 non-synonymous protein-altering somatic mutations in 88/99 samples. In 11 184 
tumors no mutations were detected. The somatic variants included 597 missense, 45 nonsense, 31 185 
frameshift, 24 direct splicing, and 9 indel alterations, resulting in a median of 6 somatic mutations in 186 
exonic regions per tumor (range: 0-55) (Figure 1 and Table 1). According to the PolyPhen-2 187 
algorithm, 203 mutations were classified as probably damaging, 116 as possibly damaging, 271 as 188 
benign, and 116 remained undefined. The most frequent substitutions were the C:G>T:A transition 189 
and the C:G>A:T transversion (29% and 28% of cases, respectively, Supplementary Figure 1). The 190 
complete list of somatic mutations including all the information about the type and localization of 191 
genetic alterations, the frequency of the variants in different available databases and the pathogenic 192 
classification is summarized in Supplementary Table 1. 193 
 194 
Specific genetic alterations 195 
Recurrent somatic mutations (n=56) are shown in Table 2. The most frequent alterations were 196 
missense mutations at CTNNB1, in a hot-spot region encoding serine in position 45 (n=39). CTNNB1 197 
mutations occurred in 7/39 patients (18%) with CS, 19/35 subjects (54%) with SCS, and 13/25 198 
patients (52%) with EIA. Moreover, alterations in genes encoding several members of the cadherin 199 
superfamily were identified, but only those occurring in PCDHGA6 were found in at least two 200 
samples. 201 
GNAS somatic mutations were identified in 8/74 patients with CPAs (11%), two of them with 202 
SCS and six with CS, but in none of the EIAs. In seven patients known activating mutations were 203 
found at codon 201, whereas in one patient with CS a novel probably damaging mutation was 204 
observed (76A>C, p.Lys58Gln). The 3D in silico analysis showed that lysine 58 is near the critical 205 
position 201, suggesting a functional significance for p.Lys58Gln substitution, similar to the known 206 
GNAS activating mutations (Supplementary Figure 2).  207 
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Interestingly, we found three novel somatic mutations in PRKACA in three patients with CS 208 
(p.Trp197Arg, p.245_248.del and p.Glu32Val). Although those mutations occurred outside the known 209 
hot-spot region of PRKACA in exon 7, the 3D in silico analysis pointed towards a potential pathogenic 210 
role for two of them. p.Trp197Arg mutation is located at the interface between the catalytic and the 211 
regulatory subunit. The exchange of the hydrophobic tryptophan with the hydrophilic, positively 212 
charged arginine might lead to alteration in the interaction between the subunits. Moreover, the 213 
p.245_248.del affects a region of the catalytic subunit of PKA at the interface with the regulatory 214 
subunit, likely inducing a modification that alters the binding of the regulatory to the catalytic subunit. 215 
In contrast, the mutation p.Glu32Val, with a hydrophilic, negatively charged glutamate replaced by a 216 
hydrophobic valine, is situated outside the interaction region (Figure 2).  217 
Several alterations were found in different ryanodine receptors, and those occurring in RYR1 218 
and RYR3 were recurrent. The 3D in silico analysis revealed that mutations in RYR1 (p.Arg1469Gly 219 
and p.Val3218Leu) and RYR2 (p.Lys2264Asn) were located in the clamp regions of the cytoplasmic 220 
assembly, while the mutation in RYR3 (del4516) was pinpointed in the sliding helix between 221 
transmembrane and cytoplasmic assemblies (Supplementary Figure 3). 222 
Finally, different potentially relevant “private” mutations were detected, including alterations 223 
in genes encoding ionotropic (GRIA1, GRIA2, GRID1, GRIK2, GRIN1, GRIN3B, GRIP1) and 224 
metabotropic glutamate receptors (GRM3, GRM4, GRM6). Moreover, a missense mutation in ARMC5 225 
(p.Pro866Leu) was observed in a 22-mm unilateral left adenoma associated with CS. However, no 226 
second hit at the ARMC5 gene was observed in this tumor. Finally, a probably damaging frameshift 227 
mutation (532_533insG) at TP53 was detected in a 40-mm, endocrine inactive, oncocytic adenoma. 228 
Unfortunately, no follow-up data were available to ascertain the clinical course of this patient during 229 
the post-operative period. 230 
 231 
Gene enrichment and pathway analysis 232 
The gene enrichment analysis identified 605/706 (86%) mutated genes associated with GO terms. 233 
Interestingly, Ca2+-signaling, collagen formation, and extracellular matrix organization were 234 
recognized as the most significantly represented pathways (Supplementary Table 2). The gene family 235 
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analysis further showed that eight cytokines and growth factors, 60 transcription factors, including 236 
ATRX and MED12, 16 protein kinases, including PRKACA, 14 oncogenes, including CREB1, 237 
CREBBP, CTNNB1, and GNAS, and four tumor suppressor genes, including APC and TP53 were 238 
included among the mutated genes. None of them were mutated in more than one sample 239 
(Supplementary Table 3).  240 
 241 
Genotype-phenotype correlation and transcriptome analysis 242 
No statistically significant relationship was found between the mutation frequency and clinical data 243 
(sex, age, tumor size, and cortisol secretion pattern). We classified patients into three groups according 244 
to the known or potential biological consequences of the most frequent mutations: subjects with 245 
mutations in genes encoding components of the classic Wnt/β-catenin pathway (CTNNB1, APC, 246 
APC2, PCDH15, PCDHA8, PCDHB11, PCDHA10, PKP2), those with alterations in genes encoding 247 
components of the cAMP/PKA pathway (GNAS, PRKACA, PRKAR1A, CREB1, CREBBP, ADCY3, 248 
GRM3, GRM4, GRM6), and those with mutations in genes encoding components of Ca2+-dependent 249 
signaling (CACNA1C, CACNA1E, CACNG8, RYR1, RYR2, RYR3, GRIA1, GRID1, GRIK2, GRIN1, 250 
GRIN3B, GRIP1) (Supplementary Table 4). The results of the unsupervised binary clustering analysis 251 
and the relationship between the genetic landscape of tumors and the clinical phenotype of the three 252 
groups of patients are shown in Figure 3A and Supplementary Table 5. Patients with mutations in 253 
genes encoding components of the Wnt/β-catenin pathway were older, had larger tumors, and carried a 254 
higher total number of mutations than those without these aberrations (P<0.05). In contrast, patients 255 
with mutations in the genes encoding component of the cAMP/PKA pathway were more frequently 256 
female and younger, in comparison to subjects not carrying mutations (P<0.01). Mutations in genes 257 
encoding components of Ca2+-dependent signaling were associated with a higher number of mutations 258 
when compared to those without (P=0.001), whereas no difference in clinical and hormonal 259 
parameters was evident.  260 
The results of the unsupervised clustering according to the results of the transcriptome 261 
analysis are shown in Figure 3B and C. After considering the expression level, transcriptome profile 262 
could clearly identify four groups and well separated patients with CS from those with EIA and SCS, 263 
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and tumors with mutations of the cAMP/PKA pathway from those with mutations in the Wnt/β-264 
catenin or without mutations in one of those two pathways, showing significant enrichments in 265 
calcium-related genes (Figure 3B). Surprisingly, restricting the analysis only to genes of the Ca2+ 266 
signaling pathway, the transcriptome profile was also able to clearly divide the patients in four groups. 267 
The four clusters showed a good separation in patients with CS vs those with EIA or SCS, as well as 268 
tumors with mutations in the cAMP/PKA vs Wnt/β-catenin pathway (Figure 3C).  269 
 270 
Combined genetic and genomic analysis 271 
We further analyzed current WES data in combination with those from SNP array profiling available 272 
for a subgroup of 14/99 ACAs (three with CS, seven with SCS, and seven with EIA) (17). As 273 
summarized in Table 3, some large chromosomal regions (16p13.3-13.2, 19p13.3-12, 7p22.3-22.1, 274 
11p15.5, 20q13.3) and several genes were affected by recurrent CN gains, including genes involved in 275 
Wnt/β-catenin (APC2 in two samples), cAMP/PKA pathways (PRKACA, PRKR1B, AKAP8 in two 276 
samples) or Ca2+-dependent signaling (CACNA1H in five samples, CACNA1A and CACNA1B in two 277 
samples). There was no significant difference in total number of CNA between tumors with or without 278 
somatic mutations. 279 
In 4/14 tumors no somatic mutations were detected by WES. One of those (CS) showed a 280 
large amplification at 19p13.2-12 including the genes AKAP8, CACNA1A, PDE4C and PRKACA. The 281 
second tumor (SCS) had amplifications at 7p22.2, which included PRKAR1B and 16p13.3. The third 282 
sample (EIA), presented a CN gain at chr11p15.5 and several micro-amplifications, whereas the last 283 
one (SCS), did not show any CNA in regions or genes with presumed functional relevance.  284 
 285 
Systematic review of genetic data available in unilateral adrenocortical tumors  286 
We compared the genetic findings of the present analysis with WES data available in the literature for 287 
ACA (n=69 CPA) and ACC (n=176) (Supplementary Table 6). The analysis of PRKACA wild-type 288 
benign tumors (n=94 CPA+25 EIAs) showed that mutations in genes involved in cAMP/PKA pathway 289 
were present only in CPA (20% of cases), whereas alterations of genes involved in Wnt/β-catenin 290 
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signaling were mutated in 49% of CPA and in 76% of EIAs. Alterations in genes involved in Ca2+-291 
dependent signaling were found in 14% of CPA and in 16% of EIA. 292 
We performed an unsupervised clustering with all WES data available for ACAs (n=168), 293 
subdividing the mutations according to the three groups defined above (Supplementary Figure 4). We 294 
also performed a canonical pathway analysis considering all the 168 ACA samples together and 295 
subdividing them into the three groups (49 CPA with PRKACA mutations, 94 CPA without PRKACA 296 
mutations and 25 EIA, Supplementary Table 7). In brief, genes involved in the “cancer pathways” 297 
were present in all groups, while genes of the “calcium signaling pathway”, “collagen formation” or 298 
“ECM organization” were not recorded among the PRKACA mutated CPAs. 299 
Finally, we observed that 23% of somatic mutations observed in our cohort were previously 300 
reported in at least one of the 176 ACC samples and 6% in at least two ACCs (Supplementary Table 6 301 
and Supplementary Figure 5). As expected, mutations in CTNNB1, the most frequent alterations, 302 
were detected in 15% of ACC and in 25% of ACA (34% of PRKACA wild-type CPA and 52% of 303 
EIA). Interestingly, mutations in different members of proto-cadherin family were frequently observed 304 
in 13% of CPA negative for PRKACA mutations, 24% of EIA and 15% of ACC.  305 
 306 
Discussion 307 
The present study represents the most comprehensive genetic characterization of unilateral ACA. In 308 
this large European series we analyzed also for the first time endocrine inactive adenomas that 309 
represent the most frequent but less investigated type of ACAs. By restricting the investigation to 310 
patients without mutations in the predominant hot-spot region of PRKACA (p.Leu206Arg), WES 311 
analysis highlights substantial heterogeneity of the genetic background of cortisol-producing and 312 
endocrine inactive ACAs, and separates well those tumors from aldosterone-producing ACA (27, 28). 313 
Overall, we identified 706 somatic mutations with a median of 6 per tumor. Many of the 605 mutated 314 
genes encoded components of the cAMP/PKA, the Wnt/β-catenin or, more surprisingly, the Ca2+-315 
dependent signaling pathway.  316 
Among genetic alterations of the cAMP/PKA pathway, GNAS somatic mutations were the 317 
most frequent, being associated with cortisol production, accordingly with published data (7, 9-10). In 318 
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addition to the previously reported hot-spot mutations, a novel substitution p.Lys58Gln was found in a 319 
patient with CS with potential functional relevance in our in silico model. Likewise, three novel 320 
somatic mutations in PRKACA were detected in three CPA associated with CS. Interestingly, in silico 321 
data provide evidence that the p.Trp197Arg substitution and the p.245-248 deletion may be able to 322 
alter the interaction between the catalytic and the regulatory subunit of PKA, similarly to what 323 
described for the p.Leu206Arg mutation (11). Moreover, the essential role of the phosphorylation site 324 
Trp197 in the binding to PKA regulatory subunit was already described in 1997 (29). In contrast, the 325 
localization of the mutation p.Glu32Val outside known interacting regions of the catalytic subunit, do 326 
not allow any speculation on the biological relevance of this substitution. Other mutated components 327 
of the cAMP pathway included PRKAR1A, CREB1 (cAMP responsive element binding protein), 328 
CREBBP (CREB binding protein) and three genes encoding metabotropic glutamate receptors 329 
(mGluRs, GRM3, GRM4, GRM6). The mutated mGluRs in our cohort belong to the group II and III 330 
mGluRs, which are G-protein-coupled receptors involved in regulation of intracellular cAMP levels. 331 
Interestingly, mGluR3 has been previously suggested to be involved in the regulation of 332 
steroidogenesis in adrenocortical tissues (30). Considering the relationship with the clinical data, 333 
mutations in component of the cAMP/PKA pathway occur invariably in young patients with cortisol-334 
secreting tumors. Those results are in line with the data previously published by our group (6, 8) and 335 
others (7, 9-10), confirming that additional alterations of the cAMP pathway, apart from the well-336 
known PRKACA mutations, are associated with a severe hormonal phenotype and, likely, early 337 
diagnosis. 338 
Among mutations affecting genes of the Wnt/β-catenin pathway, as expected, the most 339 
common were somatic mutations in CTNNB1 (39% of cases). They occurred more frequently in 340 
patients with SCS and EIA (54% and 52% of cases, respectively) than in those with CS (18%), as 341 
previously reported (15). These findings may further confirm a predominant role of CTNNB1 342 
mutations in early adrenocortical tumorigenesis. Among the components of the Wnt/β-catenin 343 
pathway, genes encoding for the plakophilin (PKP2), member of the arm-repeat (armadillo) gene 344 
family, the adenomatosis polyposis coli (APC) and APC2, and four members of the protocadherin 345 
family (PCDH15, PCDHA8, PCDHA10, PCDHB11) were recognized. Protocadherins play a major 346 
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role in cell-cell adhesion and interfere with the β catenin signaling proliferation pathway (31). Some 347 
members of the protocadherin family have recently been recognized as candidate tumor suppressor 348 
genes (31), and somatic mutations have been reported in squamous cell carcinoma, colon 349 
adenocarcinoma and melanoma (see COSMIC, http://cancer.sanger.ac.uk/cosmic/gene/analysis). 350 
Moreover, protocadherins may play a role in cell-cell adhesion and interfere with the Wnt/β-catenin 351 
signaling pathway (32), supporting the hypothesis that alterations of this Wnt/β-catenin regulatory 352 
signal may be relevant for adrenocortical tumorigenesis. In this context, it is important to mention that 353 
the regulator of Wnt/β-catenin pathway ZNRF3, recently reported as one of the most frequently altered 354 
genes in ACC (15), was not identified among mutated genes in our ACA series. In general and 355 
similarly to what previously reported for CTNNB1 mutations, the genetic alterations in components of 356 
the Wnt/β-catenin pathway were mostly found in older patients with larger and inactive tumors (19). 357 
Among Ca2+-dependent signaling pathways, genes encoding Ca2+ receptors (CACNA1C and 358 
CACNA1E), ryanodine receptors (RyRs), ionotropic glutamate receptors (iGluRs) and one glutamate 359 
receptor interacting protein (GRIP1) were included. The RyRs are intracellular Ca2+-release channels 360 
found on the sarcoplasmic reticulum of myocytes and on the endoplasmic reticulum of several non-361 
muscular organs (33). There is some evidence on the potential role of RyR alterations on adrenal 362 
function (34). According to our in silico analysis of RYR1 and RYR2 mutations and considering that 363 
the interaction between transmembrane and cytoplasmic domains of those receptors is an important 364 
mechanism in Ca2+ release modulation (35), it is well conceivable that the mutations found in our 365 
cohort may be biologically relevant. Several genes responsible for regulation of intracellular Ca2+ 366 
levels are known or suspected to be involved in the pathogenesis of endocrine tumors, such as 367 
aldosterone-producing adenomas (KCJN5, ATP1A1, ATP2B3, and CACNA1D) (27, 28) and GH-368 
secreting pituitary adenomas (36, 37). In contrast, the role of alterations of Ca2+ signaling in the 369 
pathogenesis of CPA is not well understood, even though it has been demonstrated that adrenal 370 
fasciculata cells express high levels of T-type and L-type Ca2+ channels that may regulate cortisol 371 
secretion (38). Additionally, Ca2+ channels could be involved in molecular mechanisms of apoptosis 372 
regulation and cancer transformation (39), leading us to speculate on the proliferative role of this 373 
pathway in adrenocortical cells. Interestingly, the transcriptome analysis performed on our 374 
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independent cohort clearly showed that the expression of Ca2+ signaling-related genes in ACAs not 375 
associated with primary hyperaldosteronism is able to classify patients into meaningful clusters. In 376 
fact, the unsupervised clustering restricted to the expression levels of those genes, provided a good 377 
separation of patients with CS from those with SCS and EIA, and tumors with mutations in the cAMP-378 
PKA pathway from those with Wnt/β catenin alterations. This finding, together with the identification 379 
of somatic mutations in Ca2+ signaling genes in our study, provides indirect evidence for a role of 380 
Ca2+-related pathways in the tumorigenesis and steroidogenesis of non-aldosterone secreting ACAs. 381 
Further studies will be necessary to unravel the specific underlying mechanisms.  382 
Additional insights come from the combined analysis with CNA available from a previous 383 
SNP array profiling (17) in a well representative subgroup of present ACAs (three CS, seven SCS, and 384 
seven EIA), including four samples without any somatic mutations, four with mutations in the Wnt/β 385 
catenin pathway, four with mutations in the cAMP/PKA pathway and two samples without known 386 
driver mutations. Here, we observed amplifications in several components of the Wnt/β-catenin, 387 
cAMP/PKA or Ca2+-dependent signaling pathways. While this provides additional evidence for a 388 
major role in the pathogenesis of ACA, no differences were observed between ACA with or without 389 
somatic mutations. 390 
According to the results of the pathway analysis, components of Ca2+ signaling, collagen 391 
formation, and extracellular matrix organization were among the most significantly represented. 392 
Extracellular matrices (ECM) are secreted molecules composed of glycoproteins, collagens, 393 
glycosaminoglycans and proteoglycans that can regulate cell migration, differentiation, proliferation 394 
and survival by communicating with intracellular cytoskeleton and growth factor signals (40). 395 
Interestingly, a putative role for ECM expression has been hypothesized in the development of human 396 
adrenal cortex (41). Moreover, a previous transcriptome study on ACAs identified enrichment in 397 
genes related to ECM (42). However, we observed only “private” mutations in ECM and collagen 398 
formation pathways and it is unclear whether they derive from proliferative processes or might 399 
represent early events in adrenocortical tumorigenesis.  400 
We also performed an unsupervised clustering considering the WES data available for all 401 
ACA together (n=168) and separated for CPAs with or without PRKACA mutations (n=49 and 94, 402 
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respectively), providing results similar to that obtained in our present series (Supplementary Figure 403 
4). In addition, in this very large series, we observed that most genetic alterations in the cAMP/PKA 404 
signaling pathway were not associated with alterations at the Wnt/β-catenin or Ca2+-dependent 405 
signaling pathway, further confirming their major role in the pathogenesis of CPAs.  406 
The analysis of the genetic landscape of ACAs and ACCs provides indirect evidence for the 407 
existence of an adenoma-carcinoma sequence in adrenocortical tumors. For instance, the frequent 408 
C:G>T:A transitions observed in our patients has been found to be a feature of most cancer types (43), 409 
including ACC (12). Moreover, 6% of somatic mutations identified in our series were previously 410 
observed in at least two ACC samples (12, 20-21), giving support to a potential role of early genetic 411 
alterations in a multistep malignant transformation process. In this context, recurrent mutations in the 412 
hot-spot region of CTNNB1, were among the most commonly observed alterations in ACA and ACC. 413 
Thus, it is tempting to speculate that an adenoma-to-carcinoma multistep progression might occur in a 414 
subset of adrenocortical tumors bearing CTNNB1 mutations, with β-catenin activating mutations as an 415 
early step in adrenocortical tumorigenesis. In sharp contrast, 11/99 tumors did not show any detectable 416 
genetic alteration by exome-sequencing. This finding might be due to limitation of the WES technique 417 
or to the pathogenesis of some ACA, which should be further evaluated for different genetic 418 
aberrations (alterations in intronic regions, alternative splicing, or gene fusions).  419 
One limitation of the current study is the lack of functional data so that we can only speculate 420 
on the biological role of newly identified genetic variants. However, also due to the large number of 421 
“private” mutations, this was beyond the scope of this report that was focused on providing a 422 
comprehensive overview of acquired genetic findings and potential genotype/phenotype correlations. 423 
Thus, targeted functional experiments will be required to characterize mutations not described in the 424 
literature. In contrast, the large samples size, including for the first time also endocrine inactive 425 
adenomas, with detailed clinical characterization and the integration of previous WES data available 426 
for cortisol-secreting adenomas and carcinomas are relevant strengths of this collaborative project.  427 
In summary, our study represents the largest sequencing effort on sporadic unilateral 428 
adrenocortical adenomas and demonstrates the heterogeneity of the genetic background of ACAs 429 
without PRKACA p.Leu206Arg mutation. Apart from the known somatic mutations, no other recurrent 430 
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mutation can alone explain the processes that lead to tumor formation and hormone hypersecretion. 431 
However, the provided landscape and the genetic alterations in newly described pathways (i.e. Ca2+-432 
dependent signaling) are shedding light on the pathogenesis of adrenocortical tumors and are 433 
providing a solid basis for future molecular analysis. 434 
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Figure legends  623 
 624 
Figure 1. Total number of somatic mutations in each adrenocortical adenoma (n=99) evaluated by 625 
next generation exome sequencing (median: 6 mutations per tumor). 626 
 627 
Figure 2. In silico analysis of the 3D structure changes of three novel somatic mutations in PRKACA 628 
gene (589A->G, p.Trp197Arg; 95T->A, p.Glu32Val; and deletion in position 731-745, p.245-248).  629 
a) wild type; b) the p.Trp197Arg mutation is at the interface between the catalytic and regulatory 630 
subunit. The exchange of the hydrophobic tryptophan with the hydrophilic, positively charged arginine 631 
leads to changes in this interaction. The p.245_248.del also affects a region of the catalytic subunit of 632 
PKA at the interface with the regulatory subunit. The deletion of this region probably leads to 633 
modification of the 3D structure and affects the binding of the regulatory to the catalytic subunit. The 634 
mutation p.Glu32Val is situated outside the interaction region between the catalytic and regulatory 635 
subunits of PKA or any other reported interaction region of catalytic subunit of PKA.  636 
 637 
Figure 3. A. Heat map of the most recurrent somatic mutations classified according to their known or 638 
potential biological consequences: mutations in genes encoding components of Wnt-β catenin 639 
pathway, those in genes encoding members of the cAMP/PKA pathway, and mutations in genes 640 
involved in Ca2+-signaling (n=99 samples). The relationship with the total number of somatic 641 
mutations and clinical parameters is also shown. B and C. Transcriptome analysis of the cohort of 642 
additional 41 adenomas. The unsupervised clustering performed according to the expression level 643 
from whole transcriptome profiling is shown in B, whereas the clustering restricted to Ca2+ signaling-644 
related genes is shown in C. The relationship with somatic mutations and clinical parameters, as well 645 
as the heat map of under-/over-expressed genes in the two pathways is also shown.  646 
 647 
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